Non-psychoactive cannabidiol (CBD), one of the active compounds in medical cannabis, significantly reduced clinical signs of multiple sclerosis (MS)-like disease in an experimental autoimmune encephalomyelitis mouse model. Researchers found that CBD promoted the increase of inflammatory-suppressor cells called myeloid-derived suppressor cells.
The findings were reported in the study “Cannabidiol Attenuates Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis Through Induction of Myeloid-Derived Suppressor Cells,” published in the journal Frontiers in Immunology.
Medical cannabis contains more than 100 pharmacologically active compounds (called cannabinoids), which have been shown to exert potent anti-inflammatory effects and to be potential therapies for a number of autoimmune diseases, including MS.
In MS, evidence supports the potential of CBD, one of the most studied cannabinoids, along with tetrahydrocannabinol (THC), to modulate spasticity, as well seizures, inflammation, pain, anxiety, and other conditions. The fact that CBD does not have the psychoactive properties (the so-called “high”) that accompany THC, makes it a more attractive therapeutic.
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
To receive MS news and information via e-mail, Please Click here
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
